May 2 Financial Quick Takes: Magenta, Clovis, Atomwise

Magenta follow-on comes with haircut
Stem cell transplant company Magenta Therapeutics Inc. (NASDAQ:MGTA) raised $56.3 million in a follow-on underwritten by J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow. At $13.25 per share, the price represented a 22% discount to Magenta’s closing price Monday, when it proposed the offering after market hours.

Loan to help Clovis fund Phase III trial
Clovis Oncology Inc. (NASDAQ:CLVS) will receive up to $175 million in non-dilutive funding from TPG Sixth Street Partners to fund the Phase III ATHENA trial of PARP inhibitor Rubraca rucaparib as first-line maintenance treatment for advanced ovarian cancer...